171 related articles for article (PubMed ID: 10550566)
41. Combination cyclophosphamide and etoposide in treatment of small cell lung cancer.
Leung WT; Shiu WC; Pang JC
Med Oncol Tumor Pharmacother; 1990; 7(1):31-4. PubMed ID: 2160034
[TBL] [Abstract][Full Text] [Related]
42. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
Einhorn LH; Pennington K; McClean J
Semin Oncol; 1990 Feb; 17(1 Suppl 2):32-5. PubMed ID: 2154857
[TBL] [Abstract][Full Text] [Related]
43. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party.
Br J Cancer; 1996 Feb; 73(3):406-13. PubMed ID: 8562352
[TBL] [Abstract][Full Text] [Related]
44. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
Earl HM; Rudd RM; Spiro SG; Ash CM; James LE; Law CS; Tobias JS; Harper PG; Geddes DM; Eraut D
Br J Cancer; 1991 Sep; 64(3):566-72. PubMed ID: 1654983
[TBL] [Abstract][Full Text] [Related]
45. Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.
Sessa C; Zucchetti M; Torri V; Pagani O; D'Incalci M; Gentili D; Martinelli G; deJong J; Alerci M; Cavalli F
Ann Oncol; 1993 Aug; 4(7):553-8. PubMed ID: 8395871
[TBL] [Abstract][Full Text] [Related]
46. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Albain KS; Crowley JJ; Hutchins L; Gandara D; O'Bryan RM; Von Hoff DD; Griffin B; Livingston RB
Cancer; 1993 Aug; 72(4):1184-91. PubMed ID: 8393365
[TBL] [Abstract][Full Text] [Related]
47. Combination chemotherapy with oral etoposide.
Johnson DH; Hainsworth JD; Hande KR; Greco FA
Semin Oncol; 1992 Dec; 19(6 Suppl 14):19-24. PubMed ID: 1336896
[TBL] [Abstract][Full Text] [Related]
48. Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients.
Fujiwara Y; Ohune T; Okusaki K; Niitani K; Sumiyoshi H; Takemoto Y; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1996; 37(4):327-31. PubMed ID: 8548877
[TBL] [Abstract][Full Text] [Related]
49. A phase II study of oral etoposide in elderly patients with small cell lung cancer.
Smit EF; Carney DN; Harford P; Sleijfer DT; Postmus PE
Thorax; 1989 Aug; 44(8):631-3. PubMed ID: 2477908
[TBL] [Abstract][Full Text] [Related]
50. Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.
Mead GM; Thompson J; Sweetenham JW; Buchanan RB; Whitehouse JM; Williams CJ
Cancer Chemother Pharmacol; 1987; 19(2):172-4. PubMed ID: 3032470
[TBL] [Abstract][Full Text] [Related]
51. Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study.
Sorio R; Toffoli G; Crivellari D; Bearz A; Corona G; Colussi AM; Libra M; Talamini R; Veronesi A
J Chemother; 2006 Apr; 18(2):188-91. PubMed ID: 16736888
[TBL] [Abstract][Full Text] [Related]
52. Oral etoposide in small-cell lung cancer.
Comis RL
Semin Oncol; 1986 Sep; 13(3 Suppl 3):75-8. PubMed ID: 3020704
[TBL] [Abstract][Full Text] [Related]
53. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
54. Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
Katoh O; Yamada H; Hiura K; Aoki Y; Kuroki S
J Clin Pharmacol; 1991 Dec; 31(12):1155-60. PubMed ID: 1662234
[TBL] [Abstract][Full Text] [Related]
55. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
Minami H; Ando Y; Sakai S; Shimokata K
J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
[TBL] [Abstract][Full Text] [Related]
56. Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer.
Blumenreich MS; Sheth SP; Miller CL; Farnsley ES; Kellihan MJ; Joseph UG; Hamm JT; Seeger J; Robinson LH; Hagan PC
Am J Clin Oncol; 1994 Apr; 17(2):163-5. PubMed ID: 8141109
[TBL] [Abstract][Full Text] [Related]
57. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients.
Maulard-Durdux C; Dufour B; Hennequin C; Chrétien Y; Delanian S; Housset M
Cancer; 1996 Mar; 77(6):1144-8. PubMed ID: 8635136
[TBL] [Abstract][Full Text] [Related]
59. Daily oral etoposide in the treatment of cancer.
Einhorn LH
Semin Oncol; 1991 Feb; 18(1 Suppl 2):43-7. PubMed ID: 1846980
[TBL] [Abstract][Full Text] [Related]
60. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
Cunningham D; Cummings J; Blackie RB; McTaggart L; Banham SW; Kaye SB; Soukop M
Med Oncol Tumor Pharmacother; 1988; 5(2):117-23. PubMed ID: 2842552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
